Liraglutide vs Retatrutide
First-generation daily GLP-1 agonist vs investigational triple agonist (GLP-1/GIP/glucagon) — comparing established therapy with next-generation multi-receptor approach.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Liraglutide | Retatrutide |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Triple agonist (GLP-1/GIP/Glucagon) |
| Receptor Targets | GLP-1 receptor only | GLP-1, GIP, and Glucagon receptors |
| Administration | SC injection daily | SC injection weekly |
| Max Weight Loss (Trials) | ~8% (SCALE, 3mg dose) | ~24.2% (Phase II, 12mg dose) |
| Approval Status | FDA/EMA approved (Saxenda/Victoza) | Phase III investigational |
| Dosing Frequency | Once daily | Once weekly |
| CV Outcomes Data | LEADER trial: 13% MACE reduction | No CV outcomes trial yet |
| Half-Life | ~13 hours | ~6 days |
Mechanism of Action
Liraglutide
Liraglutide Mechanism:
Liraglutide is a GLP-1 analogue with 97% homology to native GLP-1, modified with a C16 fatty acid chain enabling albumin binding and a ~13-hour half-life.
Key actions: 1. **GLP-1 receptor activation** — Appetite suppression via hypothalamic signalling 2. **Glucose-dependent insulin secretion** — Pancreatic beta-cell stimulation 3. **Glucagon suppression** — Reduces hepatic glucose output (glucose-dependent) 4. **Gastric emptying delay** — Increased satiety
As a single-receptor agonist, Liraglutide's effects are limited to the GLP-1 pathway. Its daily dosing reflects the relatively short half-life.
Retatrutide
Retatrutide Mechanism:
Retatrutide is an investigational triple agonist targeting three metabolically important receptors simultaneously:
1. **GLP-1 receptor** — Appetite suppression and insulin secretion (similar to Liraglutide/Semaglutide) 2. **GIP receptor** — Enhances insulin sensitivity, modulates fat metabolism, and complements GLP-1 effects 3. **Glucagon receptor** — Increases hepatic energy expenditure, promotes lipolysis, and enhances thermogenesis
The glucagon receptor component is unique to Retatrutide vs dual agonists like Tirzepatide. Glucagon receptor activation drives additional energy expenditure — estimated at 100-150 kcal/day — beyond appetite suppression alone. This "burn more + eat less" dual effect may explain the unprecedented weight loss results.
The engineered half-life of ~6 days enables once-weekly dosing.
Clinical Trial Evidence
Liraglutide Clinical Studies
Design: Meta-analysis
Participants: 25,572 participants
For individuals with normal weight, both semaglutide and liraglutide are generally more effective for treating T2DM. However, considering the potential for semaglutide to cause hypoglycemia, liraglutide may be the optimal choice for T2DM treatment to minimize the risk of hypoglycemia.
View study — PubMed 40619508Design: Meta-analysis
GLP- 1 agonists such as liraglutide and semaglutide effectively lower body weight and BMI in patients who suffer from weight recurrence or suboptimal clinical response after undergoing MBS. However, future studies are still warranted to investigate the most appropriate protocols for management.
View study — PubMed 40237975Design: Meta-analysis
Participants: 33,354 participants
GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity. Understanding the different risk profiles of GLP-1 RAs helps clinicians make informed treatment decisions by balancing therapeutic benefits with potential side effects.
View study — PubMed 40804463Design: Meta-analysis
Participants: 19 participants
Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.
View study — PubMed 39134066Retatrutide Clinical Studies
Design: Meta-analysis
Participants: 137 participants
Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
View study — PubMed 39911047Design: Meta-analysis
Participants: 24 participants
Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile.
View study — PubMed 39968298Design: Meta-analysis
Females lost more weight than males when treated with GLP-1RAs for weight reduction. The sex difference in weight reduction became more pronounced as the degree of weight reduction increased. Indications for obesity could magnify this sex difference.
View study — PubMed 40040445Design: Meta-analysis
Participants: 2,600 participants
GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints.
View study — PubMed 40489581Benefits Comparison
Liraglutide Unique Benefits
- Proven cardiovascular mortality benefit (LEADER)
- 15+ years of real-world safety data
- Approved for adolescent obesity (12+)
- Well-characterised pharmacokinetics
- Established titration protocols
Shared Benefits
- Appetite suppression via GLP-1 pathway
- Weight loss with metabolic improvements
- Reduction in cardiovascular risk factors
- Improved glycaemic control
Retatrutide Unique Benefits
- Unprecedented weight loss (~24% in Phase II)
- Triple receptor engagement for synergistic metabolic effects
- Dramatic liver fat reduction (NAFLD potential)
- Weekly dosing convenience
- Superior glycaemic control potential
Research & Evidence
Liraglutide Research
Liraglutide has an extensive evidence base: the SCALE obesity programme (5,000+ patients), LEADER cardiovascular outcomes trial (9,340 patients, 3.8 years), and 15+ years of post-marketing surveillance. It was the first GLP-1 RA approved for both diabetes and obesity, and the first with proven cardiovascular benefit.
Retatrutide Research
Retatrutide's evidence is limited to Phase II (338 patients for obesity, 281 for T2DM, ~48 weeks maximum). Results are remarkable but require Phase III confirmation. The TRIUMPH programme (~18,000 patients across multiple trials) is underway, with primary results expected 2026-2027. No cardiovascular outcomes trial has been completed.
Head-to-Head Analysis
Direct Comparison:
No head-to-head trial has compared Liraglutide and Retatrutide.
Efficacy Gap: Retatrutide's Phase II results showed mean weight loss of 24.2% at the highest dose (12mg) over 48 weeks — approximately 3x greater than Liraglutide's 8% in the SCALE programme. This represents the largest treatment effect seen with any obesity pharmacotherapy.
Mechanistic Advancement: Retatrutide adds two receptor targets (GIP + Glucagon) beyond Liraglutide's single GLP-1 pathway. The glucagon component drives energy expenditure increases not achievable with GLP-1 alone.
Maturity vs Potential: Liraglutide has 15+ years of clinical use, a cardiovascular outcomes trial (LEADER), and extensive real-world data. Retatrutide has one Phase II trial with 338 patients — extremely promising but very early-stage evidence.
Protocol Comparison
Liraglutide Protocol
Liraglutide Approved Protocols:
For Obesity (Saxenda): Titration: 0.6mg daily → increase by 0.6mg weekly → target 3.0mg daily. Route: Subcutaneous injection (abdomen, thigh, upper arm). Duration: Long-term. Discontinue if <5% weight loss at 12 weeks on 3mg.
For T2DM (Victoza): Start 0.6mg daily → 1.2mg → max 1.8mg daily.
⚠️ Note: Prescription medication. Daily injection required.
Retatrutide Protocol
Retatrutide Theoretical Protocols (Phase II-Based):
Dosing (Phase II): Titration: Starting doses of 1-4mg weekly, escalating to 8mg or 12mg weekly over 24 weeks. 12mg weekly dose showed maximum efficacy.
Routes: - Subcutaneous injection — once weekly
Duration: 48-week data available. Long-term effects unknown.
⚠️ Disclaimer: Retatrutide is investigational. Not approved for clinical use in any jurisdiction.
Safety Profiles
Liraglutide Safety
Liraglutide Safety Profile (Extensive Data):
Common: Nausea (39%), diarrhoea (21%), constipation (19%), vomiting (16%). GI effects typically resolve within 4-8 weeks.
Serious but rare: Pancreatitis (<0.4%), gallbladder events (2.5% vs 1.0% placebo), injection site reactions.
LEADER trial: 13% MACE reduction. No increase in thyroid cancer in humans (rodent C-cell signal not confirmed clinically).
15+ years of post-marketing data with no unexpected safety signals. Established safety in adolescents (12+).
Retatrutide Safety
Retatrutide Safety Profile (Phase II Only):
Common: Nausea (25-50% dose-dependent), diarrhoea (22%), vomiting (12%), decreased appetite (10%). GI effects comparable to other incretin therapies.
Dose-dependent: Higher doses (12mg) had more GI side effects but discontinuation rates remained low (~6%).
Glucagon receptor concerns: Theoretical hepatic effects, hyperglycaemia risk — not observed in trials to date.
Limited safety database (338 obesity patients, 48 weeks). Long-term safety, cardiovascular outcomes, and rare events are unknown pending Phase III completion.
The Verdict
Liraglutide represents the proven first generation of GLP-1 therapy — reliable, well-characterised, with cardiovascular outcomes data and 15+ years of clinical experience. Retatrutide represents a potential paradigm shift — its Phase II weight loss of 24.2% is the highest recorded for any obesity pharmacotherapy, driven by the novel addition of glucagon receptor agonism to the incretin platform. However, Retatrutide is years from potential approval and its long-term safety is unknown. For current clinical practice, Liraglutide (and its successors Semaglutide/Tirzepatide) remain the standard. Retatrutide is the most watched investigational obesity compound in development.
Frequently Asked Questions
Conclusion
Liraglutide and Retatrutide bookend the evolution of incretin-based obesity pharmacotherapy — from single GLP-1 agonism to triple GLP-1/GIP/glucagon agonism. Liraglutide's LEADER trial, paediatric approval, and 15+ years of clinical experience make it a validated, trusted option. Retatrutide's Phase II results showing 24.2% weight loss represent a potential step-change in obesity treatment, approaching bariatric surgery outcomes without surgery. The glucagon receptor component adds thermogenic energy expenditure beyond what any approved incretin therapy achieves. Both require medical supervision; Retatrutide remains investigational pending Phase III completion.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Liraglutide nor Retatrutide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.